Auriga is out with its report today on Thermo Fisher Scientific TMO, raising its PT to $73.
In a note to clients, Auriga writes, "Given TMO's solid end market demand, continued margin expansion, strong cash flow and attractive product portfolio, we view TMO's current discount (14x) to the sector median (19.5x) as unwarranted. Our $73 price target is based on 16x our new 2012 estimate of $4.70, discounted 1 year at 10%."
Auriga maintains Buy on Thermo Fisher Scientific.
Shares of TMO closed Tuesday at $61.08.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsAurigaHealth CareLife Sciences Tools & Servicesthermo fisher scientific
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in